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Background: B-cell lymphoma 6 (BCL6) protein, an evolutionarily conserved zinc finger transcription factor, showed
to be highly expressed in various human cancers in addition to malignancies in the lymphoid system. This study
investigated the role of BCL6 expression in breast cancer and its clinical significance in breast cancer patients.
Methods: Expression of BCL6 protein was assessed using in situ hybridization and immunohistochemistry in 127 breast
cancer patients and 50 patients with breast benign disease as well as in breast cell lines. Expression of BCL6 was
restored or knocked down in two breast cancer cell lines (MCF-7 and T47D) using BCL6 cDNA and siRNA, respectively.
The phenotypic change of these breast cancer cell lines was assessed using cell viability MTT, Transwell invasion,
colony formation, and flow cytometry assays and in a xenograft mice model. Luciferase reporter gene, immunoblot,
and qRT-PCR were used to investigate the molecular events after manipulated BCL6 expression in breast cancer cells.
Results: BCL6 protein was highly expressed in breast cancer cell lines and tissue specimens and expression of BCL6
protein was associated with disease progression and poor survival of breast cancer patients. In vitro, the forced
expression of BCL6 results in increased proliferation, anchorage-independent growth, migration, invasion and
survival of breast cancer cell lines, whereas knockdown of BCL6 expression reduced these oncogenic properties of
breast cancer cells. Moreover, forced expression of BCL6 increased tumor growth and invasiveness in a nude mouse
xenograft model. At the gene level, BCL6 was a target gene of miR-339-5p. Expression of BCL6 induced expression of
CXCR4 and cyclinD1 proteins.
Conclusions: The current study demonstrated the oncogenic property of BCL6 in breast cancer and further study
could target BCL6 as a novel potential therapeutic strategy for breast cancer.
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Breast cancer is the most common worldwide malignancy
in women, accounting for approximately 29% of new
cancer cases annually in women in the United States
[1]. Despite considerable advances in diagnostic and
therapeutic approaches over the past decades, breast
cancer is still the second most common cause of can-
cer death in women [1]. Better understanding of the
molecular mechanisms and gene alterations in breast
cancer could lead to more effective control of breast
cancer clinically. To date, numerous tumor suppressor* Correspondence: woozson@yahoo.com
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and further studies of these gene alterations and functions
will assist in revealing the molecular mechanisms of breast
cancer initiation and progression [2].
To this end, human B-cell lymphoma 6 (BCL6) is a
95 kDa nuclear protein, belonging to the BTB/POZ
(BR-C, ttk and bab/Pox virus and Zinc finger) domain
family of transcription factors. BCL6 protein has been
reported as a master regulator of B lymphocyte develop-
ment and growth [3,4] and altered BCL6 protein expres-
sion was implicated in pathogenesis of diverse human
hematologic malignancies, especially in the diffuse large B
cell lymphoma (DLBCL), the most common lymphoma in
adults [5-7]. Overexpression of BCL6 was frequently shown
in DLBCL patients due to a functional mutation in the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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senescence of primary mouse embryonic fibroblasts and
BCL6 expression also dramatically extends the replicative
lifespan of primary human B cells [8]. Recently, BCL6
protein was also shown to be highly expressed in various
human cancers other than malignancy in the lymphoid
system. For example, Kanazawa et al. showed that BCL6
protein was expressed in normal epidermis and epidermal
neoplasms, suggesting that expression of BCL6 protein
may be associated with differentiation in normal and
neoplastic epidermal cells [9]. Chamdin et al. reported
that BCL6 was expressed in neuroblastoma, expression
of which was significantly associated to poor survival of
the patients [10]. In the mammary glands, BCL6 protein
was expressed in the mammary epithelium in nonpregnant
and early pregnancy animals [11] and overexpression
of BCL6 prevented the duct formation and apoptosis
in murine mammary epithelium [11,12]. However, BCL6
protein was overexpressed in breast cancer tissues, es-
pecially in high-grade ductal breast cancer compared
to normal mammary gland tissues [12,13]. BCL6 expression
was able to induce expression of tumor metastasis-related
genes in breast cancer cell lines [14]. These data suggested
that BCL6 may possess an oncogenic function in breast
cancer development. However, contradicted data did show
that BCL6 expression was inversely associated with breast
cancer cell lymph node metastasis, but associated with
survival of breast cancer patients [14]. Overall, the role of
BCL6 protein in human cancers other than in the lymph-
oid system remains to be determined. Thus, in this study,
we first determined expression of BCL6 protein in breast
cancer tissues and cell lines, and then associated BCL6
expression with disease progression and prognosis. After
that, we investigated the role of BCL6 expression in regu-
lation of breast cancer cell proliferation, migration, inva-
sion, and survival in vitro and in xenografts models. We
also explored the underlying molecular events of BCL6 ac-
tion in breast cancer cells.
Methods
Cell lines and culture
Human breast cancer MCF-7, T47D, SKBR3, MDA-
MB-453, MDA-MB-435S, and BT549 cell lines, a hu-
man breast non-tumorigenic MCF-10A cell line, and a
human mammary epithelial (HMEC) cell line were
obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA) and cultured under the
ATCC-recommended conditions. All cells were main-
tained in a humidified incubator at 37°C and 5% CO2.
Breast tissue specimens
In this study, we collected two different cohorts of human
breast tissue specimens, i.e., for in situ hybridization and
immunohistochemistry, we recruited 127 patients withbreast cancer and 50 patients with breast benign disease
who underwent surgical treatment at The First Affiliated
Hospital, Anhui Medical University (Hefei, China) between
2003 and 2006; for qRT-PCR, fresh tissue specimens from
30 breast cancer and 25 breast benign disease patients
were prospectively collected between 2010 and 2011
from the same hospital. The fresh tissue specimens were
immediately placed in a cryovial after surgery, snap-frozen,
and stored in liquid nitrogen until use. Breast cancer
patients who had undergone chemotherapy or radiation
therapy before surgery were excluded. All breast cancer
patients were female and received radical mastectomy
or modified radical mastectomy. These 127 breast can-
cer patients were followed-up for a median 60 months.
A protocol to use patient samples was approved by
the Biomedical Ethics Committee of Anhui Medical
University and a written informed consent was obtained
from each patient.
In situ hybridization and immunohistochemistry
Formalin-fixed and paraffin-embedded tissue specimens
from 127 breast cancer patients and 50 breast benign
disease patients were used to construct tissue microarrays
and cut into 4-μm-thick sections. For in situ hybridization,
digoxin-labeled antisense oligonucleotide probes for
BCL6 cDNA were obtained from Boshide Biotech Co.





For immunohistochemical analysis of BCL6 expression
in tissue samples, a rabbit anti-BCL6 polyclonal antibody
was obtained for Santa Cruz Biotechnologies (Santa Cruz,
CA, USA) and used at a dilution of 1:100 according to
our previous studies [15,16].
Expression of BCL6 mRNA and protein in breast tissue
specimens were reviewed and scored by two pathologists
(QW and ZSW) using a light microscope (Olympus) using
the staining intensity and percentage of tissue staining,
i.e., 10% percent or more tumor cells stained were con-
sidered as positive, whereas <10% tumor cells stained
with any intensity was considered as negative.
Plasmid constructions and generation of stable
BCL6-expressing cell lines
The coding sequence of human BCL6 transcript variant
1 (GenBank accession #NM−001706) was cloned into
a mammalian expression vector pReceiver (GeneCopoeia,
Guangzhou, China) according to the manufacture’s
protocol. After DNA sequence confirmation, this vector
was named as pReceiver-BCL6 (BCL6). MCF-7 cells
were then stably transfected with pReceiver-BCL6 or
the empty pReceiver plasmids (VEC) to establish stable
Wu et al. BMC Cancer 2014, 14:418 Page 3 of 12
http://www.biomedcentral.com/1471-2407/14/418cells, MCF-7-BCL6, with forced expression of BCL6 and
their control cells, MCF-7-VEC, respectively.
Transfection of siRNA and miRNA
To knockdown BCL6 expression or manipulate miRNA
expression, we choose T47D and MCF-7 cells as a pair
of model cell lines for gene transfection. Briefly, cells
(1.0 ×105 /well) were seeded in 6-well plates and transiently
transfected with BCL6 small interfering RNA (siRNA) or
control scrambled siRNA duplex (GenePharma, Shanghai,
China) or with 2’-O methylated single-stranded miR-
339-5p antisense oligonucleotides (ASO) vs. its negative
control or miR-339-5p mimics (all from GenePharma) vs.
its negative control using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. The sequences of BCL6 siRNA and scram-
bled control siRNA duplex were listed in Additional file 1:
Table S1.
RNA isolation and quantitative polymerase chain reaction
Total cellular RNA was isolated using a Trizol reagent
(Invitrogen) according to manufacturer’s instructions.
qRT-PCR was then performed to detect expression of
BCL6, GAPDH, miR-339-5p, U6, and common tumor-
related genes as described previously [15,17,18]. The
sequence of the primers used for qRT-PCR was summa-
rized in Additional file 1: Table S2.
Protein extraction and Western blot
Total cellular protein and western blot analysis were
performed according to previous studies [15,19]. The
antibodies used were as follows: a rabbit anti-BCL6
polyclonal antibody (Santa Cruz Biotechnologies), a
mouse anti-cyclinD1 monoclonal antibody (Santa Cruz
Biotechnologies), a rabbit anti-CXCR4 (Bioss, Beijing,
China), and a mouse anti-GAPDH monoclonal antibody
(Santa Cruz Biotechnologies).
Assays for cell phenotypic changes
Cell phenotypic changes after gene manipulations included
proliferation, soft agar colony formation, cell migration
and invasion in MCF-7 and T47D/MDA-MB-453 cells
and the corresponding assays were performed as described
previously [15,17-19]. In addition, we performed the cell
wound healing assay to analyze tumor cell migration cap-
acity. Briefly, T47D cells were seeded into 6-well plates
and transfected with a BCL6 siRNA or NC vector. Upon
cells reached totally confluence, scratching was done using
a plastic tip. The wounded monolayers were incubated
at 37°C in 1640 containing 10% FBS with or without
mitomycin C (10 μg/ml, Sigma, St Louis, MO, USA) to
block mitosis. Photos were taken at different periods of
time under a microscope and the wound healing after
scratched was measured daily.Flow cytometry assay
Cell apoptosis was assayed using the Annexin V-Apoptosis
Detection kit (BestBio, Shanghai, China) according to
the manufacturer’s instructions. All the experiments were
performed using a FACScalibur cytometer (BD Biosciences,
San Jose, CA). Cell cycle distribution was analyzed using
the PI method. Each experiment was performed in trip-
licate and repeated at least once.
Nude mouse breast cancer cell xenograft assay
All animal work was performed according to the animal
care and use regulations of Anhui Medical University with
the approved protocol by Biomedical Ethics Committee of
Anhui Medical University. Briefly, 5 × 106 MCF-7-VEC and
MCF-7-BCL6 cells were suspended in 120 μl Matrigel/PBS
at a radio of 1:1 (v/v) and then injected into the mammary
fat pad of female BALB/c-nu (Slaccas, Hunan, China). The
day before injection, one estrogen pellet (17β-estradiol,
0.72 mg/pellet, Innovative Research of America, Sarasota,
FL) was implanted into each mouse. Tumor growth was
detected by measuring the tumor mass twice a week using
a formula = (length x width2)/2. The mice were ultimately
sacrificed on Day 27 after implantation. Primary tumors
and tumors metastasized to other organs, such as the lung
and liver, were collected for further analysis.
Luciferase reporter assay
The 3’UTR region of BCL6 was cloned to the psiCHECK-2
vector, including luciferase reporter gene. BCL6 3’UTR was
amplified with primers of 5’-CCAGCCACAAGACCGT
CCAT-3′ and 5′-CTCCGCAGGTTTCGCATTT-3′ and
then inserted into the XhoI and NotI sites of the
psiCHECK-2 vector. A psiCHECK-2 construct containing
3’UTR of BCL6 with a mutated sequence of miR-339-5p
was also generated. All constructs were verified by DNA
sequencing. After that, psiCHECK-2-BCL6 3’UTR and
psiCHECK-2-mut-BCL6 3’UTR were co-transfected with
20 pmol miRNA-339-5p mimics or its negative control into
breast cancer cells using Lipofectamine 2000 as described
previously [15,17]. Firefly luciferase activity was normal-
ized to Renilla luciferase activity. All experiments were
performed in triplicate and repeated twice.
Statistical analyses
All statistical analyses were performed using SPSS software
for Windows (version 13.0; SPSS, Chicago, IL, USA).
Differences between groups were compared using Pearson’s
chi-square test for qualitative variables and Student’s
t-test for continuous variables. Kaplan-Meier curves
were constructed to determine patient relapse-free
survival (RFS) and overall survival (OS). The statistical
differences in survival among subgroups were compared
using the log-rank test. P value <0.05 was considered
statistically significant.
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Increase in BCL6 expression in breast cancer cell lines
and tissues
Expression of BCL6 mRNA in breast cancer and non-
tumorigenic cell lines was analyzed by qRT-PCR and
the data showed levels of BCL6 mRNA were significantly
higher in breast cancer cell lines than in non-tumorigenic
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Figure 1 Expression of BCL6 mRNA and protein in human breast canc
expression in eight human mammary cell lines was analyzed by qRT-PCR. (
breast cancer (BC) and 25 breast benign disease tissue specimens (BD) by q
situ hybridization and immunohistochemistry (Magnification: ×400). (d) Kap
according to BCL6 expression.BCL6 mRNA level was also significantly higher than in
breast benign disease tissue specimens (P < 0.01; Figure 1b).
After that, we confirmed these data in additional co-
hort of samples that included archival formalin-fixed
paraffin-embedded breast tissue specimens from 127
breast cancers and 50 breast benign diseases using in
situ hybridization and immunohistochemistry. As shown
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Table 1 Expression of BCL6 in breast cancer and benign
breast disease tissues
BCL6 mRNA BCL6 protein
Group n Positive, n (%) Positive, n (%)
Benign breast disease 50 5 (10.0)* 3 (6.0)*
Breast cancer 127 68 (53.5) 41 (32.3)
Note: * P <0.01.
Table 2 Association of BCL6 protein expression with
clinicopathological parameters from breast cancer
patients
Parameter n BCL6 protein
Positive, n (%) P value
Age (years)
≤ 35 6 2 (33.3) 0.253
35-55 84 31 (36.9)
> 55 37 8 (21.6)
Tumor size (cm)
≤ 2 44 7 (15.9) 0.004
>2 83 34 (41.0)
Lymph node metastasis
No 58 13 (22.4) 0.029
Yes 69 28 (40.6)
Grade
I 28 4 (14.3) 0.003
II 75 23 (30.7)
III 24 14 (58.3)
Stage
I 28 3 (10.7) 0.006
II - III 99 38 (38.4)
Estrogen receptor
Negative 56 22 (39.3) 0.134
Positive 71 19 (26.8)
Progesterone receptor
Negative 64 22 (34.4) 0.611
Positive 63 19 (30.2)
c-erbB-2
low 93 32 (34.4) 0.397
high 34 9 (26.5)
Ki67
≤50% 50 8 (16.0) 0.002
>50% 77 33 (42.9)
Values in bold are significant (P < 0.05).
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in breast benign disease tissues (both P < 0.01).
Association of BCL6 protein expression with
clinicopathological and survival data from breast
cancer patients
We then associated BCL6 expression with clinicopathologi-
cal features and survival of breast cancer patients and found
that expression of BCL6 protein was positively associated
with tumor size (P = 0.004), higher tumor grade (P = 0.003),
tumor lymph node metastasis (P = 0.029), advanced clinical
stages (P = 0.006) and Ki67 labeling index (P = 0.002) of
breast cancer (Table 2). Kaplan-Meier analyses showed
that patients with BCL6 protein-negative primary tumors
exhibited higher five-year overall and disease-free survivals
than patients with BCL6 protein-positive tumors (P = 0.026
and 0.029, respectively; Figure 1d).
Expression of BCL6 promoted breast cancer cell
proliferation, migration, and invasion, and inhibited
apoptosis in vitro
We assessed the effects of forced expression of BCL6 on
breast cancer cell growth, migration, and invasion in vitro.
Based on the expression levels of BCL6 in breast cancer
cell lines (Figure 1a), we therefore selected T47D and
MCF-7 cells as model cell lines for the loss-of-function and
gain-of-function analyses. BCL6 siRNA and cDNA was
transiently transfected into T47D and MCF-7 cells, respect-
ively. We observed that BCL6 siRNA decreased expression
of BCL6 in T47D cells (Additional file 2: Figure S1a),
whereas BCL6 cDNA transfection increased BCL6 ex-
pression in MCF-7 cells (Additional file 2: Figure S1b).
Expression of BCL6 protein promoted MCF-7 cell viability
(P < 0.01; Figure 2a, right), whereas depletion of BCL6
expression reduced T47D cell viability (P < 0.01; Figure 2a,
left). Wound healing assays showed that BCL6 depletion
leaded to slower closing of the scratch wounds in T47D
cells compared with the control vector-transfected cells
(Figure 2b, left). We also treated these cells with mitomy-
cin C to block cell mitosis, which therefore allowed us to
analyze cell migration in absence of cell proliferation. Our
data revealed that treatment with mitomycin C did not
affect the time course of wound closure, indicating that
the effect of BCL6 depletion on cell migration was not
dependent on cell proliferation (Figure 2b, right).Furthermore, forced expression of BCL6 significantly
increased the G2/M phase population in MCF-7 cells, but
had more profound effect on G1 phase population with an
8.41% increase compared to the control (P < 0.01; Figure 2c).
The increased BCL6 expression significantly reduced apop-
tosis of MCF-7 cells, with a 6.72% decrease compared with
the control (P < 0.01; Figure 2d).
In addition, depletion of BCL6 expression signifi-
cantly decreased colony formation of T47D cells by 46.4%
compared to the control (P < 0.01; Figure 3a). In contrast,
forced BCL6 expression significantly increased colony
formation in MCF-7 by 30.0% compared to controls





















































Figure 2 (See legend on next page.)
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Figure 2 Effects of BCL6 on regulation of breast cancer cell phenotype. (a) Cell viability MTT assay. Cells were transiently transfected with
BCL6 siRNA vs. negative control (NC) or BCL6 cDNA vs. control vector (VEC), respectively and then seeded in 96-well plates (3 × 103 per well) and
grown for 4 days for MTT assay. (b) Wound healing assay. T47D cells were grown and transiently transfected with BCL6 siRNA or negative control
(NC), the wounded monolayers were cultured in the absence (left) or presence (right) of mitomycin C. (c) Flow cytometric analysis of cell cycle
distribution in MCF-7 cells after gene transfection. (d) Flow cytometric analysis of apoptosis in MCF-7 cells after gene transfection. The average of
apoptosis rate is presented as mean ± SD. All experiments were repeated at least three times. **P < 0.01.
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breast cancer cell migration and invasion capacity. Due to
the weak invasive capacity of T74D cells, we choose another
cell line with relatively high expression of BCL6, MDA-
MB-453, to perform loss-of-function experiments in theFigure 3 Effects of BCL6 expression on regulation of breast cancer co
assay. After gene transfection, cells were seeded in 0.35% top agarose and
counted after 14 days incubation. (b) Tumor cell migration and invasion as
BCL6 siRNA or negative control (NC) for 72 h. MCF-7 cells were grown and
Cells in the upper chamber were removed and those cells migrated to the loTranswell assay. The number of migrated MDA-MB-453
cells was reduced to 53.2% after transfection with BCL6
siRNA (P < 0.01; Figure 3c), and was 66.9% lower than
control cell for cell invasion (P < 0.01; Figure 3c). In
contrast, forced expression of BCL6 protein increased thelony formation and migration and invasion capacity. (a) Soft agar
10% FBS in six-well plates in triplicate. The number of colonies was
say. MDA-MB-453 cells were grown and transiently transfected with
transiently transfected with BCL6 cDNA or vector-only (VEC) for 48 h.
wer layer of the inner chamber were stained and counted. **, P < 0.01.
Wu et al. BMC Cancer 2014, 14:418 Page 8 of 12
http://www.biomedcentral.com/1471-2407/14/418capacity of MCF-7 cell migration and invasion compared to
the control cells (P < 0.01; Figure 3c).
Expression of BCL6 promoted growth and invasiveness of
MCF-7 cells in nude mouse xenografts
To further determine the effect of BCL6 expression in
regulation of breast cancer proliferation and progression
in vivo, we injected MCF-7-VEC and MCF-7-BCL6 cells
orthotopically into the mammary fat pad of female BALB/c
nude mice, respectively. The data showed both groups of
cells formed palpable and measurable tumors, while MCF-
7-BCL6 cell xenografts were significantly larger than those
of MCF-7-VEC xenografts (P < 0.05; Figure 4a). Histology
of xenografts showed that tumors derived from MCF-7-
BCL6 cells were poorly encapsulated and highly invasive
(Figure 4b). Interestingly, tumor cell emboli were observed
in MCF-7-BCL6 xenografts but not in the control xeno-
grafts, suggesting that BCL6 expression potentially pro-














Figure 4 Effects of BCL6 expression on regulation of MCF-7 xenograf
transplanted into the mammary fat pad of female BALB/c-nu, respectively.
(a) Xenograft growth curve of MCF7-VEC and MCF7-BCL6-derived tumors o
sections. More aggressive behavior was observed in the margin of tumor n
cells (blue arrow). Tumor embolus (red arrow head) was visualized in bloodExpression of BCL6 increased expression of CXCR4
and cyclinD1
Thus far, we have demonstrated the effects of BCL6 expres-
sion in breast cancer. We next determined the possible
underlying mechanism. In our study, we analyzed the ex-
pression levels of key genes involved in cell proliferation,
survival and metastasis [20-23] after transfection with
BCL6 cDNA or control by qRT-PCR and observed that ex-
pression of BCL6 increased cyclinD1 and CXCR4 mRNA
expression in MCF-7 cells (Figure 5a). Using western blot,
we confirmed that expression of cyclinD1 and CXCR4
protein was increased by transfection of BCL6 cDNA in
MCF-7 cells, while depletion of BCL6 expression decreased
their expression in T47D cells (Figure 5b), suggesting that
BCL6 might regulate expression of these oncogenes.
BCL6 is a direct target of miR-339-5p
Our previous study revealed that expression of BCL6 was
down-regulated by miR-339-5p [18]. To verify BCL6 as theMCF-7-BCL6 
VEC
BCL6
t growth in nude mice. MCF7-VEC and MCF7-BCL6 cells were
The volume of xenografts was measured twice a week and calculated.
ver 27 days. (b) Hematoxylin and eosin staining of tumor xenograft
odule of MCF-7-BCL6 cells (red arrow) compared to that of MCF-7-VEC
vessel (Magnification: ×200). *, P < 0.05; **, P < 0.01.













Figure 5 Effects of BCL6 expression on CXCR4 and cyclinD1 expression. (a) qRT-PCR. MCF-7 cells were transiently transfected with BCL6
cDNA or negative control vector and grown for 2 days. (b) Western blot. MCF-7 and T74D cells were transiently transfected with BCL6 cDNA,
BCL6 siRNA, or negative control vector and grown for 2 days and subjected to Western blot. *, P < 0.05.
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analyses were performed to detect the expression levels of
BCL6 in breast caner cells transfected with either miR-339-
5p mimics or miR-339-5p ASO. Expression of miR-339-5p
resulted in substantial reduced levels of BCL6 mRNA and
protein in T47D cells, while depletion of miR-339-5p
expression using miR-339-5p ASO significantly increase
in levels of BCL6 mRNA and protein (Figure 6a). Bioinfor-
matic analysis utilized the algorithm of Targetscan [24]
showed that BCL6 mRNA contains a 3’-UTR element
complementary to the miR-339-5p binding site. Forced
expression of miR-339-5p reduced the activity of a lucifer-
ase reporter gene fused to the full length wild-type BCL6
3’UTR, indicating that miR-339-5p directly targets BCL6
(Figures 6b and c).
A previous study has reported that expression of miR-
339-5p inhibited breast cancer cell migration and inva-
sion [18]. We therefore proceeded to determine whether
BCL6 was involved in miR-339-5p-mediated cell migra-
tion and invasion. We first depleted BCL6 expression bysiRNA and co-transfected the cells with miR-339-5p
ASO and observed that depletion of BCL6 expression
significantly abrogated miR-339-5p ASO-induced tumor
cell migration and invasion, indicating that BCL6 plays a
critical role at the downstream of miR-339-5p (Figure 6d).
Discussion
In the current study, we first detected BCL6 expression
in breast cancer vs. breast benign disease tissue speci-
mens and found that levels of BCL6 mRNA and protein
were significant higher in breast cancer tissues than in
breast benign disease tissues. Expression of BCL6 protein
was associated with tumor size, lymph node metastasis,
advanced clinical stages, higher tumor grade and also Ki67
labeling index in breast cancer. Moreover, Kaplan-Meier
analyses showed the association of BCL6 protein expression
with poor overall and relapse-free survivals of patients.
After that, we assessed the effects of forced expression or
depletion of BCL6 protein on breast cancer cell viability,
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Figure 6 BCL6 as the direct target gene of miR-339-5p in breast cancer cells. (a) qRT-PCR and Western blot. miR-339-5p mimics or
miR-339-5p ASO was transiently transfected into T47D cells and subjected to analysis of BCL6 expression. (b) The binding site of BCL6 3′-UTR
and miR-339-5p. (c) Luciferase reporter assay. T47D cells were transfected with psiCHECK-2-BCL6 3′-UTR or psiCHECK-2-BCL6 mutated 3′-UTR
plus either miR-339-5p mimics or negative control and subjected to luciferase reporter assay. (d) Tumor cell migration and invasion assay and
Western blot. MCF-7 cells were grown and transiently transfected with miR-339-5p ASO, miR-339-5p ASO plus BCL6 siRNA or scrambled
sequence oligonucleotides as negative control for 2 days and subjected to migration, invasion and western blot assays. *P < 0.05; **P < 0.01.
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creased tumor cell viability, migration, invasion, and sur-
vival as well as expression of cyclinD1, and CXCR4 in vitro.
BCL6 expression also induced formation and growth of xe-
nografts in nude mice. The bioinformatic analysis and lucif-
erase assay showed that BCL6 expression could be directly
targeted by miR-339-5p. In conclusion, our current study
demonstrated that the reduced miR-339-5p expression
[our previous data (ref)] promoted BCL6 expression, whichin turn induces cyclinD1 and CXCR4 expression for in-
duction of breast cancer cell proliferation and invasion.
Future studies will investigate whether target of BCL6
expression could be useful as a novel therapeutic strategy
for breast cancer.
Clinically, patients with early stage breast cancer have
relatively high survival rates, but most of breast cancer
still progress unnoticeably and lead to 30% of patients
relapse with a distant metastatic disease [25]. For past
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epidermal growth factor receptor 2 (HER-2/neu), estrogen
receptor (ER) and progesterone receptor (PR), have been
identified and routinely used in clinic to predict prognosis
and therapeutic response of the patients [26,27]. In the
current study, we showed BCL6 as a potential biomarker
to predict overall and disease-free survival of breast cancer
patients. Indeed, BCL6 protein has been comprehensively
accepted to play a role in supporting hematologic cell neo-
plastic transformation. Overexpression of BCL6 has been
observed in 40% of DLBCL [28], 14% of follicular lymph-
omas [29], and 48% of nodular lymphocyte-predominant
Hodgkin lymphomas [30]. BCL6 expression has also been
observed in skin squamous cell carcinoma [9], neuroblast-
oma [10], melanoma [31], and breast cancer [12-14]. In
breast cancer, Logarajah et al. showed that BCL6 protein
was expressed in most of histologically high-grade ductal
breast carcinoma compared with low-grade tumors [12].
Bos et al. reported that expression of BCL6 protein was
significantly higher in breast cancer than in normal breast
tissues [13]. Another most recent study showed that high
expression of BCL6 protein associated with unfavorable
clinical outcome of ER-positive and premenopausal breast
cancer patients [32]. Our current data are consistent with
these published studies [12,13] by confirmed the onco-
genic effect of BCL6 in breast cancer, similar to those in
hematologic malignancies.
However, Pinto et al. showed that expression of BCL6
protein was significantly down-regulated in metastatic
lymph nodes than in the corresponding primary breast
cancer [14]. The reason for this discrepancy is unknown,
but led us to studying the effects of BCL6 on breast cancer
cell lines. Using gain and loss-of-function approaches, our
in vitro data demonstrated that expression of BCL6 did en-
hance breast cancer cell viability, anchorage-independent
growth, migration, and invasion capacity. Concordantly,
expression of BCL6 promoted low-invasive MCF-7 cell
growth and invasiveness in vivo. These data demonstrated
that BCL6 is an oncogene or has oncogenic effects on
breast cancer cells. These data were consistent with a
previous study showing that BCL6 expression prevented a
mammary epithelial cell line to form the ducts and apop-
tosis [12]. However, it remains unknown how BCL6 con-
tribute to breast cancer development or progression.
Thus, we then explored the underlying molecular events.
CXCR4 has been identified as an important chemokine
receptor in regulating cell migration, invasion and me-
tastasis in breast cancer [23]. CyclinD1 is an essential
cell cycle regulator for progression through G1 phase and
is a candidate proto-oncogene [33]. We analyzed expression
of CXCR4 and cyclinD1 in BCL6 expressed or knocked
down breast cancer cell lines and found that expression of
these genes was all up-regulated by BCL6 expression.
Moreover, our previous study revealed that expression ofBCL6 was regulated by miR-339-5p [18], but it was un-
clear whether BCL6 is a direct target gene of miR-339-5p.
Our luciferase assay indeed confirmed that BCL6 is the
target gene of miR-339-5p. miRNAs are a class of non-
protein-coding RNAs and possess an important function
in regulation of gene expression [34]. By regulating their
target mRNAs for direct degradation or inhibition of trans-
lation, miRNAs play important roles in many biological
processes and altered miRNA expression contributes
to cancer development and progression [34]. miR-339-5p
has been implicated in regulation of cell proliferation, mi-
gration and invasion in different cancers [18,35]. Although
miR-339-5p may target different genes, BCL6 is definitely
one of them. Our current data on manipulating miR-339-5p
expression did alter effects of BCL6 on breast cancer cells.
Conclusions
Our current study demonstrated that high expression of
BCL6 associated with tumor size, lymph node metastasis,
advanced clinical stages, higher tumor grade, and Ki67
labeling index as well as poor prognosis of breast cancer.
Manipulation of BCL6 expression using the gain and loss
of function approaches affected breast cancer cell viability,
apoptosis, migration, invasion and gene expression in vitro
and in nude mice. At the gene level, BCL6 induced CXCR4
and cyclinD1 expression and BCL6 is the target gene of
miRNA, miR-339-5p. Future studies will further investigate
the underlying molecular mechanisms by which BCL6 is
overexpressed in breast cancer and BCL6 expression con-
tributes to breast cancer progression. In addition, we will
also determine whether BCL6 is a potential biomarker for
prediction of breast cancer prognosis or as a therapeutic
target for breast cancer patients.
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